Similares

1. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations.
2. B-Cell Responses in Chronic Chagas Disease: Waning of Trypanosoma cruzi-Specific Antibody-Secreting Cells Following Successful Etiological Treatment.
3. Benznidazole, itraconazole, and their combination for the treatment of chronic experimental Chagas disease in dogs.
4. Perspectives for a new drug candidate for Chagas disease therapy.
5. Reduced Trypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease.
6. Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi.
7. Antiparasitary and antiproliferative activities in vitro of a 1,2,4-oxadiazole derivative on Trypanosoma cruzi.
8. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
9. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR.
10. Enzymatic synthesis of amlodipine amides and evaluation of their anti-<i>Trypanosoma cruzi</i> activity.